Radiopharm Theranostics Limited (RADX) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-01, Radiopharm Theranostics Limited (NASDAQ: RADX) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $1.12 (+17.52% 1D, market cap $16.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, RADX ranks #198 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RADX carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, JAGX (Jaguar Health Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.9M) and NEUP (Neuphoria Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -11.8%, cap $16.6M). Among the 5-stock peer group, RADX leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).
For Radiopharm Theranostics Limited (RADX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #198 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 61/100 (C-) score, RADX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1.58) or 200D SMA ($3.67) invalidates the momentum regime and cuts Target Base ($1.14) toward Bear Floor ($0.89).
Radiopharm Theranostics Limited (RADX) surged +17.52% to $1.12, trading at 2% of its 52-week range ($0.9 – $16.25). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares rose 8.72% to
GE HealthCare secures CE Mark certification for MINItrace Magni and expands Copper-64 production capabilities, strengthening its PET imaging and theranostics portfolio.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RADX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RADX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Radiopharm Theranostics Limited (RADX) ranks #198 by composite RQD confidence (61/100, grade C-) and #851 by equity capitalization ($16.1M). Within this direct 5-issuer industry benchmark cohort, RADX leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. RADX currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RADX
ACTIVE
Radiopharm Theranostics Limited | C- | 61/100 | — | — | — | +17.52% | $16.1M | Benchmark Subject |
| JAGX Jaguar Health Inc. | E | 31/100 | — | 67.2% | -35.0% | -2.86% | $15.9M | /jagx-vs-radx → |
| NEUP Neuphoria Therapeutics Inc. | E | 32/100 | — | — | -11.8% | -8.93% | $16.6M | /neup-vs-radx → |
| NCEL NewcelX Ltd. | D- | 39/100 | — | — | -35.0% | -0.30% | $15.5M | /ncel-vs-radx → |
| MRKR Marker Therapeutics Inc. | D | 48/100 | — | — | -35.0% | +1.00% | $16.8M | /mrkr-vs-radx → |
Radiopharm Theranostics Limited (RADX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $16.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, Radiopharm Theranostics Limited (NASDAQ: RADX) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $1.12 (+17.52% 1D, market cap $16.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, RADX ranks #198 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RADX carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, JAGX (Jaguar Health Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.9M) and NEUP (Neuphoria Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -11.8%, cap $16.6M). Among the 5-stock peer group, RADX leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).
For Radiopharm Theranostics Limited (RADX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #198 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
RADX last traded at $1.12 (+17.52% on volume of 38,684 shares), positioning the stock -29.11% below its 50-day simple moving average ($1.58) and -69.48% below its 200-day simple moving average ($3.67). Across its 52-week range of $0.90 to $16.25, RADX sits at the 1.4% percentile with a 14-day RSI of 41.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.26).
Why RADX Stock surged +17.52% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).